abrdn World Healthcare Fund Q1 2025 Commentary
Source: SeekingAlpha
2025-06-03 08:20:00 ET
Summary
- The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.
- The top three detractors over the quarter were Novo Nordisk, uniQure and Teva Pharmaceutical Industries.
- The top three positive contributors were Roche Holding, AbbVie and AstraZeneca.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn World Healthcare Fund Q1 2025 Commentary
Aberdeen Emerging Markets Equity Income Fund Inc.
NASDAQ: AEF
AEF Trading
-3.19% G/L:
$7.58 Last:
280,885 Volume:
$7.78 Open:
AEF Latest News
March 10, 2026 04:17:00 pm
Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
